First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Renaud Descourt, Christos Chouaid, Maurice Pérol, Benjamin Besse, Laurent Greillier, Olivier Bylicki, Charles Ricordel, Florian Guisier, Radj Gervais, Roland Schott, Jean-Bernard Auliac, Gilles Robinet, Chantal Decroisette
Future Oncol 17(23) 3007-3016
摘要
摘要
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without EGFR mutations or ALK rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. The expected results are a reduction in the risk of early progression. A higher objective tumor response is also expected with the combination of chemotherapy and pembrolizumab compared with pembrolizumab alone. The study will allow a direct comparison of the proportion of patients who derive long-term benefit from the treatment. Clinical trial number: EudraCT (2020-002626-86); ClinicalTrials.gov (NCT04547504).
KM 提取结果
0 个 Figure · 0 个 KM 面板